Regeneron Pharmaceuticals, Inc. REGN
Super Investor & Insider
3
Fondi che lo detengono
#240
Rank consenso
4.3%
% dei portafogli
$3.66B
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | 1.89% | Reduce 3% | 4,458,238 | $3.44B |
| Harry Burn · Sound Shore Management | 3.91% | Reduce 14.17% | 150,960 | $116.6M |
| Mason Hawkins · Southeastern Asset Management | 4.97% | Reduce 21.19% | 130,662 | $101.0M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio includes treatments such as Eylea and Eylea HD for retinal and eye disor…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees15,343
TickerREGN
Statistics
Market Cap$63.72B
Revenue (TTM)$14.34B
Net Income$4.50B
Net Margin31.4%
EPS$41.48
P/E14.93
P/S4.30
P/B1.98
EV/EBITDA12.81
ROE14.5%
Dividend Yield0.61%
Price$606.80
Data: Twelve Data · Revenue = mcap / P/S